MYUNGMOON Pharm co.,Ltd (017180.KS)
KRW 1860.0
(-0.59%)
KRW 1860.0
(-0.59%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 12.58 Billion KRW | 72.3% |
| 2022 | 7.3 Billion KRW | 22.63% |
| 2021 | 5.95 Billion KRW | -22.67% |
| 2020 | 7.7 Billion KRW | -68.96% |
| 2019 | 24.81 Billion KRW | 161.94% |
| 2018 | 9.47 Billion KRW | 206.27% |
| 2017 | 3.09 Billion KRW | 1561.17% |
| 2016 | 186.2 Million KRW | -69.98% |
| 2015 | 620.28 Million KRW | -67.73% |
| 2014 | 1.92 Billion KRW | 1790.37% |
| 2013 | 101.67 Million KRW | -99.5% |
| 2012 | 20.35 Billion KRW | -4.57% |
| 2011 | 21.32 Billion KRW | -29.25% |
| 2010 | 30.14 Billion KRW | -11.28% |
| 2009 | 33.97 Billion KRW | 117.32% |
| 2008 | 15.63 Billion KRW | 96.59% |
| 2007 | 7.95 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 43.67 Billion KRW | 252.45% |
| 2024 Q1 | 12.39 Billion KRW | -1.53% |
| 2023 Q2 | 6.2 Billion KRW | -8.13% |
| 2023 FY | 12.58 Billion KRW | 72.3% |
| 2023 Q1 | 6.75 Billion KRW | -7.45% |
| 2023 Q4 | 12.58 Billion KRW | -6.32% |
| 2023 Q3 | 13.43 Billion KRW | 116.32% |
| 2022 Q2 | 5.38 Billion KRW | -6.87% |
| 2022 Q4 | 7.3 Billion KRW | -6.89% |
| 2022 Q1 | 5.77 Billion KRW | -2.99% |
| 2022 FY | 7.3 Billion KRW | 22.63% |
| 2022 Q3 | 7.84 Billion KRW | 45.77% |
| 2021 Q1 | 7.69 Billion KRW | -0.04% |
| 2021 Q2 | 7.14 Billion KRW | -7.19% |
| 2021 FY | 5.95 Billion KRW | -22.67% |
| 2021 Q4 | 5.95 Billion KRW | -15.02% |
| 2021 Q3 | 7 Billion KRW | -1.91% |
| 2020 FY | 7.7 Billion KRW | -68.96% |
| 2020 Q1 | 13.44 Billion KRW | -45.82% |
| 2020 Q4 | 7.7 Billion KRW | -9.89% |
| 2020 Q3 | 8.54 Billion KRW | -33.93% |
| 2020 Q2 | 12.93 Billion KRW | -3.78% |
| 2019 Q1 | 20.85 Billion KRW | 120.15% |
| 2019 Q4 | 24.81 Billion KRW | 4.55% |
| 2019 Q3 | 23.73 Billion KRW | 10.68% |
| 2019 Q2 | 21.44 Billion KRW | 2.82% |
| 2019 FY | 24.81 Billion KRW | 161.94% |
| 2018 Q1 | 4.07 Billion KRW | 31.73% |
| 2018 Q3 | 9.78 Billion KRW | 60.58% |
| 2018 Q4 | 9.47 Billion KRW | -3.16% |
| 2018 FY | 9.47 Billion KRW | 206.27% |
| 2018 Q2 | 6.09 Billion KRW | 49.52% |
| 2017 Q4 | 3.09 Billion KRW | 2668.62% |
| 2017 Q3 | 111.72 Million KRW | -14.29% |
| 2017 Q2 | 130.34 Million KRW | -12.5% |
| 2017 Q1 | 148.96 Million KRW | -20.0% |
| 2017 FY | 3.09 Billion KRW | 1561.17% |
| 2016 FY | 186.2 Million KRW | -69.98% |
| 2016 Q1 | 227.76 Million KRW | -63.28% |
| 2016 Q2 | 210.24 Million KRW | -7.69% |
| 2016 Q3 | 186.2 Million KRW | -11.43% |
| 2016 Q4 | 186.2 Million KRW | 0.0% |
| 2015 Q1 | 1.54 Billion KRW | -19.59% |
| 2015 Q2 | 1.37 Billion KRW | -11.33% |
| 2015 Q4 | 620.28 Million KRW | -33.67% |
| 2015 FY | 620.28 Million KRW | -67.73% |
| 2015 Q3 | 935.2 Million KRW | -31.76% |
| 2014 Q2 | 2.67 Billion KRW | 5175.16% |
| 2014 FY | 1.92 Billion KRW | 1790.37% |
| 2014 Q4 | 1.92 Billion KRW | -16.37% |
| 2014 Q3 | 2.29 Billion KRW | -14.07% |
| 2014 Q1 | 50.7 Million KRW | -50.13% |
| 2013 Q1 | 20.25 Billion KRW | -0.47% |
| 2013 Q3 | 20.15 Billion KRW | -0.25% |
| 2013 Q4 | 101.67 Million KRW | -99.5% |
| 2013 FY | 101.67 Million KRW | -99.5% |
| 2013 Q2 | 20.2 Billion KRW | -0.25% |
| 2012 Q4 | 20.35 Billion KRW | 0.0% |
| 2012 Q1 | 1.01 Billion KRW | 0.0% |
| 2012 FY | 20.35 Billion KRW | -4.57% |
| 2011 FY | 21.32 Billion KRW | -29.25% |
| 2011 Q3 | 1.63 Billion KRW | -15.8% |
| 2011 Q2 | 1.93 Billion KRW | -36.96% |
| 2011 Q1 | 3.07 Billion KRW | 0.0% |
| 2010 Q2 | 2.54 Billion KRW | -58.05% |
| 2010 Q1 | 6.06 Billion KRW | 0.0% |
| 2010 Q3 | 3.54 Billion KRW | 39.37% |
| 2010 FY | 30.14 Billion KRW | -11.28% |
| 2009 Q1 | 14.99 Billion KRW | -4.05% |
| 2009 FY | 33.97 Billion KRW | 117.32% |
| 2009 Q3 | 10.15 Billion KRW | -5.07% |
| 2009 Q2 | 10.69 Billion KRW | -28.69% |
| 2008 Q2 | 13.65 Billion KRW | 0.0% |
| 2008 Q3 | 13.1 Billion KRW | -4.05% |
| 2008 FY | 15.63 Billion KRW | 96.59% |
| 2008 Q4 | 15.63 Billion KRW | 19.29% |
| 2007 FY | 7.95 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 7.741% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 93.772% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 57.879% |
| HANDOK Inc. | 123.78 Billion KRW | 89.833% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -2545.169% |
| Yuhan Corporation | 60.23 Billion KRW | 79.108% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 92.232% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -12259.53% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 84.659% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -2031.798% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -108.003% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 32.06% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -687.08% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 7.741% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -10415.014% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 89.6% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 60.674% |
| JW Holdings Corporation | 20.65 Billion KRW | 39.081% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 15.116% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 58.053% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 58.053% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -5647.234% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -2067.275% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 74.612% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -182.664% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 7.741% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 33.864% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 86.529% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 58.053% |
| Yuhan Corporation | 60.23 Billion KRW | 79.108% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -19.85% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 68.834% |
| Suheung Co., Ltd. | 74 Billion KRW | 82.996% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 58.053% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -202.023% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -14.793% |
| CKD Bio Corp. | 69.43 Billion KRW | 81.875% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 63.603% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 21.971% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -3998.337% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -5647.234% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 82.549% |
| Boryung Corporation | 151.7 Billion KRW | 91.705% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 83.974% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -108.003% |
| JW Lifescience Corporation | 168 Million KRW | -7390.595% |